-
Mashup Score: 2
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma – Full Text View.
Source: www.clinicaltrials.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
The Angeles Clinic and Research Institute The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, has established an international reputation for developing new cancer therapies, providing the best in experimental and traditional treatments, and expertly guiding and training the next generation of clinicians. Date: Saturday – May 14, 2022Time: 12:00 PM (ET)|…
Source: AIM at Melanoma FoundationCategories: Hem/Oncs, Latest HeadlinesTweet-
Free Melanoma Symposium with @AIMatMelanoma @angelesclinic May 14,2022. In person and virtual. https://t.co/IX33l8KrSi #ocularmelanoma #neoadjuvant #immunotherapy leaders from @CSCancerCare @Columbia @MassGeneralNews @MDAndersonNews https://t.co/aFnAqxk3bg
-
-
Mashup Score: 0
PURPOSE This phase I study aimed to define the recommended phase II dose (RP2D) of tebentafusp, a first-in-class T-cell receptor/anti-CD3 bispecific protein, using a three-week step-up dosing regimen, and to assess its safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with metastatic uveal melanoma (mUM). METHODS In this open-label, international, phase…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In new research published in @JCO_ASCO, SKCC's Drs. Marlana Orloff & Takami Sato discuss the results of a phase I #ClinicalTrial of tebentafusp, the first systemic therapy specifically for #UvealMelanoma: https://t.co/pJcsXMTrKD #ResearchWednesday #OcularMelanoma https://t.co/nW9OHLnSGF
-
-
Mashup Score: 5
Immunocore announces FDA approval of KIMMTRAK ® ( tebentafusp- tebn ) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only FDA approved therapy for the treatment of unresectable or metastatic uveal melanoma ( mUM ) KIMMTRAK is the first T cell receptor (TCR)
Source: Immunocore PLCCategories: Hem/Oncs, Latest HeadlinesTweet-
Congratulations @Immunocore and all patients dealing with #ocularmelanoma !!! #KIMMTRAK #tebetefusp approved by @US_FDA @FDAOncology !! A major step forward for our patients. Blessed to have been part of this @angelesclinic https://t.co/nRLw7V6uUt
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marlana Orloff, MD, Associate Professor of Medical #Oncology at @KimmelCancerCtr has created an unusual niche for herself in the world of oncological clinical care and research. She specializes in rare #melanoma subtypes—specifically, #ocularmelanoma: https://t.co/H0tnC2ypQU https://t.co/OmC0SjIS11
-
-
Mashup Score: 1Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marlana Orloff, MD, Associate Professor of Medical #Oncology at @KimmelCancerCtr has created an unusual niche for herself in the world of oncological clinical care and research. She specializes in rare #melanoma subtypes—specifically, #ocularmelanoma: https://t.co/H0tnC2ypQU https://t.co/C8Y6r5NUQ1
-
-
Mashup Score: 3Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Issue Alert! The #January 5 issue features articles on rare #ocularmelanoma, #lungcancer in never-smokers, and reducing anesthesia use for #pediatric #radiation patients. Find it here: https://t.co/bOcclOkXVG #oncologynews #medtwitter https://t.co/AgX61A33Vz
-
-
Mashup Score: 2Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marlana Orloff, MD, Associate Professor of Medical #Oncology at @KimmelCancerCtr has created an unusual niche for herself in the world of oncological clinical care and research. She specializes in rare #melanoma subtypes—specifically, #ocularmelanoma: https://t.co/H0tnC2ypQU https://t.co/HShbV80x0L
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Issue Alert! The #January 5 issue features articles on rare #ocularmelanoma, #lungcancer in never-smokers, and reducing anesthesia use for #pediatric #radiation patients. Find it here: https://t.co/bOcclOkXVG #oncologynews #medtwitter https://t.co/zL9BN3Dwim
-
-
Mashup Score: 0Genetic Landscape and Emerging Therapies in Uveal Melanoma - 2 year(s) ago
Despite successful treatment of primary uveal melanoma, up to 50% of patients will develop systemic metastasis. Metastatic disease portends a poor outcome, and no adjuvant or metastatic therapy has been FDA approved. The genetic landscape of uveal melanoma is unique, providing prognostic and potentially therapeutic insight. In this review, we discuss our current understanding of the molecular and…
Source: MDPICategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a review published in Cancers, SKCC Drs. Rino Seedor, Marlana Orloff, & Takami Sato discuss their current understanding of the molecular & cytogenetic mutations in #UvealMelanoma as well as the role of #LiquidBiopsies: https://t.co/dAKNnWXPr7 #ResearchWednesday #OcularMelanoma https://t.co/LF1y31yUxT
-
#TrialTuesday: SKCC's Dr. Marlana Orloff and team are investigating the effectiveness of SD-101, a TLR 9 agonist, in patients with #UvealMelanoma that has spread to the liver: https://t.co/zaBOFKUZN4 @TriSalusLifeSci #ClinicalTrial #OcularMelanoma #JeffersonResearch https://t.co/xjabvpUE1R